R&D channel feed

Ax­some cel­e­brates mi­graine PhI­II win, shift­ing eyes to­ward a pair of Q4 sub­mis­sions

6 years ago

GSK's asth­ma bi­o­log­ic Nu­cala is one step clos­er to ap­proval in key chron­ic rhi­nos­i­nusi­tis pop­u­la­tion

6 years ago

Servi­er bags an an­ti­body spe­cial­ist in its lat­est on­col­o­gy M&A deal with plans to add the plat­form tech

6 years ago
Deals

Ahead of US IPO, Leg­end Biotech adds $150M, top-tier in­vestors to back CAR-T pipeline

6 years ago
Financing

Covid-19 roundup: Mod­er­na CEO Stéphane Ban­cel be­comes a bil­lion­aire; No­var­tis, In­cyte pitch Jakafi PhI­II to tack­le se­vere cas­es

6 years ago
Coronavirus

Mer­ck scores new ad­vance on tu­mor-ag­nos­tic front as Keytru­da beat chemo-based reg­i­mens in a type of col­orec­tal can­cer

6 years ago
Pharma

FDA OKs a tri­al for a new Covid-19 ther­a­py af­ter an un­usu­al pub­lic­i­ty cam­paign touts its po­ten­tial — with help from Rudy Giu­liani

6 years ago
Bioregnum
Coronavirus

ITeos nabs $125M as they prep Keytru­da com­bi­na­tion tri­al — if Covid-19 will let them

6 years ago
Financing

It is 'kind of a proven tech­nol­o­gy': Hep B vac­cine mak­er joins glob­al hunt for coro­n­avirus vac­cine

6 years ago
Coronavirus

Just in time to as­sure a de­ci­sion be­fore CVR dead­line, Bris­tol My­ers Squibb files NDA for Cel­gene/blue­bird CAR-T

6 years ago

Can a pair of top AveX­is alum­ni steer a new gene ther­a­py up­start to R&D glo­ry? 3 VCs bet $60M on it

6 years ago
Financing

Brii Bio gets all hands on deck for Covid-19 an­ti­body hunt, lever­ag­ing Chi­nese part­ner­s' work with re­cov­ered pa­tients

6 years ago
China
Coronavirus

In a stun­ning set­back, Amarin los­es big patent fight over Vas­cepa IP. And its high-fly­ing stock crash­es to earth

6 years ago

Covid-19 and weak da­ta force pipeline re­vamp at Rea­ta, but the best tri­als go for­ward — with some cre­ative adap­tions

6 years ago
Coronavirus

David Hal­lal bags an­oth­er whop­per round, look­ing to re­cruit more cell and gene ther­a­py up­starts to El­e­vate­Bio Base­Camp

6 years ago
Financing
Startups

New­ly-pub­lic Im­muno­vant an­nounces first proof-of-con­cept suc­cess

6 years ago

Lund­beck adds a Parkin­son's flop to its list of set­backs, writ­ing off a $1.1 bil­lion deal on mid-stage fail­ure

6 years ago

Ax­some re­ports late-stage de­pres­sion tri­al de­feat, shares wilt

6 years ago

Mer­ck and Bay­er un­veil the da­ta be­hind their CV ‘suc­cess,’ un­der­whelm­ing the in­dus­try

6 years ago

As­traZeneca says its block­buster Farx­i­ga proved to be a game-chang­er in CKD — wrap­ping PhI­II ear­ly

6 years ago
Pharma

Gilead CEO Dan O'­Day of­fers a de­tailed ex­pla­na­tion on remde­sivir ac­cess — re­as­sur­ing an­a­lysts that Covid-19 da­ta are com­ing fast

6 years ago
Coronavirus

As share buy­backs come un­der scruti­ny, what's in store for the bio­phar­ma in­dus­try?

6 years ago
Coronavirus

Strug­gling Unum ex­ecs are ready to con­sid­er a sale, merg­er or any deal that comes its way

6 years ago

VBL and its 'gene ther­a­py' can­cer treat­ment are back — with a peek at PhI­II po­ten­tial

6 years ago
Cell/Gene Tx
First page Previous page 206207208209210211212 Next page Last page
A service from the Financial Times